Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
← catalyst calendarNCT07480564 · readout ≤ 1,776 d
Sponsored by Taysha Gene Therapies, Inc. (industry) · TSHA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
4actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-08 | actual | When the study began enrolling |
| Primary completion | Jun 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rett Syndrome
Intervention
- Genetic: TSHA-102
Primary outcome
what the primary-completion date above is the date OFPrimary Safety
measured Baseline through Week 25
Permalink · TSHA's whole pipeline · Catalyst calendar · Every registered study · What changed